Nephrology Times
Advertisement
Treatment with a finerenone-empagliflozin combo leads to greater decreases in albuminuria in CKD and type 2 diabetes.
Pegcetacoplan reduced proteinuria and stabilized eGFR in adolescent patients with C3G or primary IC-MPGN.
An analysis confirmed the efficacy and safety of pegcetacoplan for patients with C3G/IC-MPGN and nephrotic range proteinuria.
Treatment effects of nefecon were consistent independent of baseline eGFR among patients with IgAN.
Infliximab therapy for Crohn’s disease is linked to a high risk for IgAN, a study found.
A study highlights the role of NPT2b in tubulointerstitial fibrosis and CKD progression.
Researchers identified three immune phenotypes of checkpoint inhibitor-induced acute interstitial nephritis.
A study assessed whether the cardiovascular and renal effects of canagliflozin are dose dependent.
Research identified the optimal biomarker combination to predict interstitial fibrosis surface in IgA nephropathy.
Survival benefits of deceased-donor kidney transplantation decrease when older patients receive lower quality organs.
Long-term data demonstrated that zigakibart reduced proteinuria and stabilized kidney function of patients with IgAN.
Moderate-to-severe chronic arteriolar lesions were found to be independent risk factors for adverse renal prognosis in IgAN.
Winners of the 2025 ERA Awards and ERA Awards for Young Investigators were recognized at the 62nd ERA Congress.
Pain coping skills training demonstrated benefits for patients on maintenance hemodialysis in a randomized clinical trial.
Hemodialysis patients reporting shorter sleep or problems sleeping had a higher mortality risk in an observational study.
Finerenone had kidney and cardiovascular benefits for patients with CKD even after an acute eGFR change occurred.
Higher cardiovascular mortality risk was associated with higher CKM syndrome stage, research showed.
The Annual Global Summit on Kidney Disease Innovations included sessions on rare diseases, human organ alternatives, and more
A dual SGLT inhibitor may have ischemic benefits for patients with CKD, T2D, and cardiovascular risks, a study found.
An analysis of CKD trials supported 3-year total slope as the primary slope-based outcome in randomized trials.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.